1. Search Result
Search Result
Results for "

(R)-3-Hydroxybutanoic acid (sodium)

" in MedChemExpress (MCE) Product Catalog:

2346

Inhibitors & Agonists

61

Fluorescent Dye

64

Biochemical Assay Reagents

1417

Peptides

1

Inhibitory Antibodies

338

Natural
Products

47

Isotope-Labeled Compounds

27

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-W015851
    (R)-3-Hydroxybutanoic acid sodium
    4 Publications Verification

    (R)-(-)-3-Hydroxybutanoic acid sodium; (R)-3-Hydroxybutyric acid sodium

    Endogenous Metabolite Metabolic Disease
    (R)-3-Hydroxybutanoic acid sodium ((R)-3-Hydroxybutyric acid) is a metabolite converted from acetoacetic acid catalyzed by 3-hydroxybutyrate dehydrogenase. (R)-3-Hydroxybutanoic acid sodium can function as a nutrition source, and as a precursor for vitamins, antibiotics and pheromones .
    (<em>R)-3</em>-<em>Hydroxybutanoic</em> acid sodium
  • HY-W051723
    (R)-3-Hydroxybutanoic acid
    4 Publications Verification

    (R)-(-)-3-Hydroxybutanoic acid; (R)-3-Hydroxybutyric acid

    Endogenous Metabolite Others
    (R)-3-Hydroxybutanoic acid is a metabolite, and converted from acetoacetic acid catalyzed by 3-hydroxybutyrate dehydrogenase. (R)-3-Hydroxybutanoic acid has applications as a nutrition source and as a precursor for vitamins, antibiotics and pheromones .
    (<em>R)-3</em>-<em>Hydroxybutanoic</em> acid
  • HY-B0228S10

    (R)-(-)-3-Hydroxybutanoic acid-13C2 sodium; (R)-3-Hydroxybutyric acid-13C2 sodium

    Endogenous Metabolite Metabolic Disease
    (R)-3-Hydroxybutanoic acid- 13C2 (sodium) is the 13C labeled (R)-3-Hydroxybutanoic acid (sodium) (HY-W015851). (R)-3-Hydroxybutanoic acid (sodium) is a metabolite converted from acetoacetic acid catalyzed by 3-hydroxybutyrate dehydrogenase. (R)-3-Hydroxybutanoic acid sodium can function as a nutrition source, and as a precursor for vitamins, antibiotics and pheromones[1][2][3].
    (<em>R)-3</em>-<em>Hydroxybutanoic</em> acid-13C2 sodium
  • HY-W015851S

    [2-13C]Sodium acetate; Sodium [2-13C]acetate; Sodium acetate-2-13C

    Endogenous Metabolite Metabolic Disease
    (R)-3-Hydroxybutanoic acid- 13C (sodium) is the 13C labeled (R)-3-Hydroxybutanoic acid sodium[1]. (R)-3-Hydroxybutanoic acid sodium ((R)-3-Hydroxybutyric acid) is a metabolite converted from acetoacetic acid catalyzed by 3-hydroxybutyrate dehydrogenase. (R)-3-Hydroxybutanoic acid sodium can function as a nutrition source, and as a precursor for vitamins, antibiotics and pheromones[2][3].
    (<em>R)-3</em>-<em>Hydroxybutanoic</em> acid-13c sodium
  • HY-W015851S2

    (R)-(-)-3-Hydroxybutanoic acid-13C4 sodium; (R)-3-Hydroxybutyric acid-13C4 sodium

    Isotope-Labeled Compounds Others
    (R)-3-Hydroxybutanoic acid-13C4 (sodium) is an active compound. (R)-3-Hydroxybutanoic acid-13C4 (sodium) can be used for kinds of research.
    (<em>R)-3</em>-<em>Hydroxybutanoic</em> acid-13C4 sodium
  • HY-P0041

    Vasopressin Receptor Neurological Disease
    F992 is an antidiuretic peptide and vasopressin (antidiuretic hormone) analogue .
    F992
  • HY-P0041A

    Vasopressin Receptor Neurological Disease
    F992 TFA is an antidiuretic peptide and vasopressin (antidiuretic hormone) analogue .
    F992 TFA
  • HY-P10218A

    PKC Inflammation/Immunology Cancer
    MANS peptide TFA is the TFA salt form of MANS peptide (HY-P10218). MANS peptide TFA is an inhibitor for myristoylated alanine-rich C kinase substrate (MARCKS), which competes with MARCKS in cells for membrane binding, and thus inhibits the stimulation of mucin secretion and tumor metastasis .
    MANS peptide TFA
  • HY-P10218

    PKC Inflammation/Immunology Cancer
    MANS peptide is an inhibitor for myristoylated alanine-rich C kinase substrate (MARCKS), which competes with MARCKS in cells for membrane binding, and thus inhibits the stimulation of mucin secretion and tumor metastasis .
    MANS peptide
  • HY-P10318

    GLP Receptor Endocrinology
    SHR-2042 is a selective agonist of the GLP-1 receptor.SHR-2042 improves glycemic control by activating the GLP-1 receptor, enhancing insulin secretion and inhibiting glucagon secretion. SHR-2042 combined with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC) promotes monomerization through the formation of micelles and improves oral absorption efficiency .
    SHR-2042
  • HY-P10200

    Bacterial Infection
    CP7-FP13-2 is a peptide with antivirulence factor and antibacterial activity. CP7-FP13-2 inhibits the formation of Staphylococcus aureus biofilm and has good antibacterial efficacy in mice .
    CP7-FP13-2
  • HY-P3462

    CGRP Receptor Metabolic Disease
    Cagrilintide is an investigational novel long-acting acylated amylin analogue, acts as nonselective amylin receptors (AMYR) and calcitonin G protein-coupled receptor (CTR) agonist. Cagrilintide induces significant weight loss and reduces food intake. Cagrilintide has the potential for the research of obesity [3].
    Cagrilintide
  • HY-P3462A

    CGRP Receptor Metabolic Disease
    Cagrilintide acetate is a non-selective AMYR/CTR agonist and long-acting acylated amylase analogue. Cagrilintide acetate causes a reduction in food intake and significant weight loss in a dose-dependent manner. Cagrilintide acetate can be used in obesity studies [3].
    Cagrilintide acetate
  • HY-P5161A

    GCGR Metabolic Disease
    FC382K10W15 TFA is a glucagon analogue and GLP-1R/GCGR agonist. FC382K10W15 TFA can be used in type 2 diabetes research .
    FC382K10W15 TFA
  • HY-P3143

    PD-1/PD-L1 Cancer
    BMSpep-57 is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction with an IC50 of 7.68 nM. BMSpep-57 binds to PD-L1 with Kds of 19 nM and 19.88 nM in MST and SPR assays, respectively. BMSpep-57 facilitates T cell function by in creasing IL-2 production in PBMCs .
    BMSpep-57
  • HY-P3143A

    PD-1/PD-L1 Cancer
    BMSpep-57 hydrochloride is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction with an IC50 of 7.68 nM. BMSpep-57 hydrochloride binds to PD-L1 with Kds of 19 nM and 19.88 nM in MST and SPR assays, respectively. BMSpep-57 hydrochloride facilitates T cell function by in creasing IL-2 production in PBMCs .
    BMSpep-57 hydrochloride
  • HY-P10271

    GLP Receptor Metabolic Disease
    RG7697 is a dual agonist for glucagon-like peptide receptor (GLP Receptor) and glucosedependent insulinotropic polypeptide receptor (GIPR), with EC50 of 5 and 3 pM, respectively. RG7697 exhibits antihyperglycemic property .
    RG7697
  • HY-P10341

    GCGR Metabolic Disease
    ZP3022 is a dual agonist of glucagon-like peptide-1 (GLP-1) and gastrin, which has the ability to continuously improve glycemic control. Meanwhile, ZP3022 can effectively increase the mass of β-cells, promote β-cell proliferation, and enhance the average islet mass. ZP3022 can be used in research for anti-diabetic treatments .
    ZP3022
  • HY-113560

    Antibiotic Fungal Phospholipase Infection
    Plipastatin B1 is a lipopeptide antibiotic, an inhibitor of phospholipase A2 (PLA2), which has antifungal activity .
    Plipastatin B1
  • HY-P1162

    SKF 100273

    Vasopressin Receptor Metabolic Disease
    (d(CH2)51,Tyr(Me)2,Arg8)-Vasopressin (SKF 100273) is a vasopressin V1 receptor selective antagonist .
    (d(CH2)51,Tyr(Me)2,Arg8)-Vasopressin
  • HY-P4895

    Oxytocin Receptor Neurological Disease
    (d(CH2)51,Tyr(Me)2,Orn8)-Oxytocin (OVT) is an oxytocin receptor antagonist. (d(CH2)51,Tyr(Me)2,Orn8)-Oxytocin can be used for the research of neurological disease .
    (d(CH2)51,Tyr(Me)2,Orn8)-Oxytocin
  • HY-P10272

    PTG-300

    Ferroportin Others
    Rusfertide is a peptide mimetic of natural hepcidin, which targets and degrades ferroportin, reduces serum iron and transferrin-saturation, and thus regulates the production of red blood cells. Rusfertide ameliorates the polycythemia vera, β-thalassemia and hereditary hemochromatosis .
    Rusfertide
  • HY-134238

    Endogenous Metabolite Neurological Disease
    Cardiolipin (Heart, Bovine) sodium is a mitochondria-exclusive phospholipid. Cardiolipin (Heart, Bovine) sodium has the potential for the research of Neurological Disease .
    Cardiolipin (Heart, Bovine) (<em>sodium</em>)
  • HY-W020035

    GPR55 Neurological Disease
    L-α-lysophosphatidylinositol Soy sodium is an endogenous ligand of GPR55. L-α-lysophosphatidylinositol Soy sodium is an endogenous lysophospholipid and endocannabinoid neurotransmitter that belongs to the class of lysophospholipids .
    L-α-lysophosphatidylinositol (Soy) (<em>sodium</em>)
  • HY-132582A

    Tau Protein
    Tau ASO-12 (murine) (sodium) is a Tau-lowering antisense oligonucleotide (ASO) for murine use, and it has the potential for the research of Alzheimer Disease. (Tau ASO-12 sequence – 5′ GCTTTTACTGACCATGCGAG 3′ )
    Tau ASO-12 (murine) (<em>sodium</em>)
  • HY-106950CS

    Diphosphofructose-1-13C (sodium); Esafosfan-1-13C (sodium); FDP-1-13C (sodium)

    Isotope-Labeled Compounds Endogenous Metabolite Others
    Fosfructose-1- 13C (sodium) is the 13C labeled Fosfructose[1].
    Fosfructose-1-13C sodium
  • HY-106950CS1

    Diphosphofructose-2-13C (sodium); Esafosfan-2-13C (sodium); FDP-2-13C (sodium)

    Isotope-Labeled Compounds Endogenous Metabolite Others
    Fosfructose-2- 13C (sodium) is the 13C labeled Fosfructose[1].
    Fosfructose-2-13C sodium
  • HY-106950CS3

    Diphosphofructose-6-13C (sodium); Esafosfan-6-13C (sodium); FDP-6-13C (sodium)

    Isotope-Labeled Compounds Endogenous Metabolite Others
    Fosfructose-6- 13C (sodium) is the 13C labeled Fosfructose[1].
    Fosfructose-6-13C sodium
  • HY-129987

    Endogenous Metabolite Metabolic Disease Endocrinology
    Estradiol 17-(β-D-Glucuronide) sodium, a metabolite of estrogen, is well known to cause intrahepatic cholestasis in humans .
    Estradiol 17-(β-D-Glucuronide) (<em>sodium</em>)
  • HY-N7755

    Estrogen Receptor/ERR Cancer
    Estradiol 3-(β-D-Glucuronide) sodium is the glucuronic acid derivative of estradiol (HY-B0141). Estradiol 3-(β-D-Glucuronide) sodium is radiolabeled for use in tumor imaging and biodistribution studies .
    Estradiol <em>3</em>-(β-D-Glucuronide) (<em>sodium</em>)
  • HY-135748A

    Toll-like Receptor (TLR) Apoptosis Infection Cancer
    Poly (I:C):Kanamycin (1:1) sodium is an isometric complex of Poly (I:C) (HY-135748) and Kanamycin (HY-16566). Poly(I:C) sodium, a synthetic analog of double-stranded RNA, is a TLR3 and retinoic acid-inducible gene I receptor (RIG-I and b>MDA5) agonist. Poly(I:C) sodium can be used as a vaccine adjuvant to enhance innate and adaptive immune responses and induce apoptosis in cancer cells . Kanamycin is an orally active antibacterial agent (Gram-negative/positive bacteria) that inhibits translocation and causes miscoding by binding to the 70S ribosomal subunit. Kanamycin shows good inhibitory activity against Mycobacterium tuberculosis (susceptible and drug-resistant) and Klebsiella pneumoniae, and can be used in the research of tuberculosis and pneumonia [3] .
    Poly (I:C):Kanamycin (1:1) (<em>sodium</em>)
  • HY-132609

    Small Interfering RNA (siRNA) Transthyretin (TTR) Neurological Disease
    Patisiran sodium is a double-stranded small interfering RNA that targets a sequence within the transthyretin (TTR) messenger RNA. Patisiran sodium specifically inhibits hepatic synthesis of mutant and wild-type TTR. Patisiran sodium can be used for the research of hereditary TTR amyloidosis [3].
    Patisiran sodium
  • HY-W854295

    PtdIns-(1,2-dioctanoyl) (sodium)

    P-glycoprotein Cancer
    Phosphatidylinositol-1,2-dioctanoyl sodium significantly inhibits transmembrane P-gp transport in a reproducible, cell line-independent, and substrate-independent manner. Phosphatidylinositol-1,2-dioctanoyl sodium plays an important role in signal transduction and cell movement .
    Phosphatidylinositol-1,2-dioctanoyl sodium
  • HY-108764

    ISIS 301012

    HCV Metabolic Disease
    Mipomersen sodium (ISIS 301012) is an antisense oligonucleotide inhibitor of apolipoprotein B (apoB). Mipomersen has anti-HCV effect and reduces the infectivity of the HCV. Mipomersen sodium can be used for the research of homozygous familial hypercholesterolemia (HoFH) .
    Mipomersen sodium
  • HY-145725

    IONIS 598769 sodium

    Others Others
    Baliforsen (sodium) is an antisense oligonucleotide (16 nucleotides) designed to target myotonic dystrophy protein kinase (DMPK) mRNA and research myotonic dystrophy.
    Baliforsen sodium
  • HY-A0213AS

    Tiludronic acid-d5 (sodium)

    Proton Pump Inflammation/Immunology
    Tiludronate-d5 (sodium)mis the deuterium labeled Tiludronate disodium. Tiludronate (Tiludronic Acid) disodium, an orally active bisphosphonate, can act an osteoregulator. Tiludronate is used for the research of the metabolic bone disorders. Tiludronate is a potent inhibitor of the osteoclast vacuolar H(+)-ATPase. Antiresorptive and anti-inflammatory properties[1][2][3][4].
    Tiludronate-d5 sodium
  • HY-B0739AS

    Cytidine diphosphate-choline-d9 (sodium); CDP-Choline-d9(sodium); Cytidine 5'-diphosphocholine-d9 (sodium)

    Endogenous Metabolite Apoptosis Neurological Disease
    Citicoline-d9 (sodium) is the deuterium labeled Citicoline sodium. Citicoline sodium salt is an intermediate in the synthesis of phosphatidylcholine which is a component of cell membranes and also exerts neuroprotective effects.
    Citicoline-d9 sodium
  • HY-109561

    EYE001; NX1838

    VEGFR Metabolic Disease Inflammation/Immunology
    Pegaptanib sodium is an RNA aptamer directed against vascular endothelial growth factor (VEGF)-165. Pegaptanib could be used for the study of neovascular age-related macular degeneration (AMD) .
    Pegaptanib sodium
  • HY-B1788S

    N-Choloyltaurine-d4 (sodium)

    Endogenous Metabolite Inflammation/Immunology
    Taurocholic acid-d4 (sodium) is the deuterium labeled Taurocholic acid. Taurocholic acid (N-Choloyltaurine) is a bile acid involved in the emulsification of fats.
    Taurocholic acid-d4 sodium
  • HY-Y0781S

    Acetylformic acid-13C (sodium)

    Endogenous Metabolite Others
    Pyruvic acid- 13C (sodium) is the 13C-labeled Pyruvic acid. Pyruvic acid is an intermediate metabolite in the metabolism of carbohydrates, proteins, and fats.
    Pyruvic acid-13C sodium
  • HY-N1429S1

    12-Deoxycholyltaurine-d5 (sodium)

    Apoptosis Endogenous Metabolite Inflammation/Immunology
    Taurochenodeoxycholic acid-d5 (sodium) is the deuterium labeled Taurochenodeoxycholic acid sodium. Taurochenodeoxycholic acid sodium salt (12-Deoxycholyltaurine sodium salt) is one of the main bioactive substances of animals' bile acid. Taurochenodeoxycholic acid induces apoptosis and shows obvious anti-inflammatory and immune regulation properties[1][2].
    Taurochenodeoxycholic acid-d5 sodium
  • HY-132613

    Small Interfering RNA (siRNA) Metabolic Disease
    Lumasiran sodium, an investigational RNA interference (RNAi) therapeutic agent, reduces hepatic oxalate production by targeting glycolate oxidase. Lumasiran sodium reduces urinary oxalate excretion, the cause of progressive kidney failure in primary hyperoxaluria type 1 (PH1) .
    Lumasiran sodium
  • HY-147080

    ARC1905

    Complement System Others
    Avacincaptad pegol (ARC1905) is an anti-C5 RNA aptamer that inhibits the cleavage of complement factor 5 (C5) into C5a and C5b. Avacincaptad pegol is being used for the study of age-related macular degeneration (AMD).
    Avacincaptad pegol sodium
  • HY-W145483

    N-Acetyl-de-O-sulfated heparin (Heparin IV-A) (sodium)

    Biochemical Assay Reagents Others
    Heparin IV-A sodium is a biochemical reagent that can be used as a biological material or organic compound for life science related research.
    Heparin IV-A sodium
  • HY-W127550

    1,2-Dipalmitoyl-sn-glycero-3-phospho-rac-(1-glycerol) (sodium)

    Biochemical Assay Reagents Others
    rac-DPPG sodium is a biochemical reagent that can be used as a biological material or organic compound for life science related research.
    rac-DPPG sodium
  • HY-113378S

    β-Hydroxybutyric acid-d4 (sodium)

    Endogenous Metabolite Metabolic Disease
    3-Hydroxybutyric acid-d4 (sodium) is the deuterium labeled 3-Hydroxybutyric acid. 3-Hydroxybutyric acid (β-Hydroxybutyric acid) is a metabolite that is elevated in type I diabetes. 3-Hydroxybutyric acid can modulate the properties of membrane lipids[1].
    <em>3</em>-Hydroxybutyric acid-d4 sodium
  • HY-N2334AS

    Chenodeoxycholylglycine-d7 (sodium); Sodium glycochenodeoxycholate-d7

    Endogenous Metabolite Apoptosis Cancer
    Glycochenodeoxycholic acid-d7 (sodium) is the deuterium labeled Glycochenodeoxycholic acid (sodium salt). Glycochenodeoxycholic acid sodium salt (Chenodeoxycholylglycine sodium salt) is a bile acid formed in the liver from chenodeoxycholate and glycine. It acts as a detergent to solubilize fats for absorption and is itself absorbed. Glycochenodeoxycholic acid sodium salt (Chenodeoxycholylglycine sodium salt) induces hepatocyte apoptosis[1][2].
    Glycochenodeoxycholic acid-d7 sodium
  • HY-P3100

    Liposome Cancer
    Orfamide A is a liposome to simulate biological phospholipid membrane. Liposomes are the main component of vesicles with concentric phospholipid bilayer membranes, which can be used to construct drug delivery systems for anti-cancer and anti-infection fields. Highly polar water-soluble payloads can be trapped in the internal aqueous space of liposomes, while lipophilic payloads can partition into and become part of the lipid bilayer. Especially for delivering antisense oligonucleotides, it can overcome problems such as inefficient cellular uptake and rapid loss in the body .
    Orfamide A
  • HY-P4146

    BI 456906

    GLP Receptor GCGR Metabolic Disease
    Survodutide (BI 456906) is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC50s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .
    Survodutide
  • HY-P4146A

    BI 456906 TFA

    GLP Receptor GCGR Metabolic Disease
    Survodutide (BI 456906) TFA is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC50s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide TFA, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide TFA has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .
    Survodutide TFA

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: